Lexeo Therapeutics develops gene therapies that aim to treat inherited heart diseases in patients with genetic cardiomyopathies. LXEO reports earnings on Mon, Dec 14, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 23 | Leerink Partners | Maintained | Buy | |
| Jun 25 | JP Morgan | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in LXEO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LXEO is in one of them and how their past LXEO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LXEO in an article yet. Here's the latest on the wider market.
About Lexeo Therapeutics
Lexeo Therapeutics is a biotechnology company based in New York that develops gene therapies for inherited heart diseases. Its candidates are designed to deliver working copies of disease-linked genes to heart muscle cells. The lead programs target Friedreich ataxia cardiomyopathy and arrhythmogenic cardiomyopathy caused by PKP2 gene mutations, and the company is also developing candidates for other genetic heart conditions. Its target patients have genetic heart diseases with few or no approved treatments.
- Headquarters
- New York, NY